Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study
Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study
JM Soto, JT Toledo, P Gutierrez … [et.al]
- Ohio American Society of Tropical Medicine and Hygiene 2002
- 147-51 tbls.;ilus
- Vol. 66, no. 2 (feb. 2002)
We studied the efficacy of WR279396, a topical formulation of aminoglycosides that cures 100 per cent of cutaneous leishmaniasis lesions in mice. We conducted what is to our knowledge the first controlled study of WR279396 therapy for clinical cutaneous l = Am. J. Trop. Med. Hyg
Leishmaniasis cutánea
Administración tópica
Bibliografía del INS4
Terapia combinada
We studied the efficacy of WR279396, a topical formulation of aminoglycosides that cures 100 per cent of cutaneous leishmaniasis lesions in mice. We conducted what is to our knowledge the first controlled study of WR279396 therapy for clinical cutaneous l = Am. J. Trop. Med. Hyg
Leishmaniasis cutánea
Administración tópica
Bibliografía del INS4
Terapia combinada